Hughes Francis M, Hill Hayden M, Wood Case M, Edmondson Andrew T, Dumas Aliya, Foo Wen-Chi, Oelsen James M, Rac Goran, Purves J Todd
Division of Urology, Department of Surgery, Duke University Medical Center, Durham, North Carolina; Department of Urology, Medical University of South Carolina, Charleston, South Carolina.
Department of Urology, Medical University of South Carolina, Charleston, South Carolina.
J Urol. 2016 May;195(5):1598-1605. doi: 10.1016/j.juro.2015.12.068. Epub 2015 Dec 18.
While bladder outlet obstruction is well established to elicit an inflammatory reaction in the bladder that leads to overactive bladder and fibrosis, little is known about the mechanism by which this is initiated. NLRs (NOD-like receptors) and the structures that they form (inflammasomes) have been identified as sensors of cellular damage, including pressure induced damage, and triggers of inflammation. Recently we identified these structures in the urothelium. In this study we assessed the role of the NLRP3 (NACHT, LRR and PYD domains-containing protein 3) inflammasome in bladder dysfunction resulting from bladder outlet obstruction.
Bladder outlet obstruction was created in female rats by inserting a 1 mm outer diameter transurethral catheter, tying a silk ligature around the urethra and removing the catheter. Untreated and sham operated rats served as controls. Rats with bladder outlet obstruction were given vehicle (10% ethanol) or 10 mg/kg glyburide (a NLRP3 inhibitor) orally daily for 12 days. Inflammasome activity, bladder hypertrophy, inflammation and bladder function (urodynamics) were assessed.
Bladder outlet obstruction increased urothelial inflammasome activity, bladder hypertrophy and inflammation, and decreased voided volume. Glyburide blocked inflammasome activation, reduced hypertrophy and prevented inflammation. The decrease in voided volume was also attenuated by glyburide mechanistically as an increase in detrusor contraction duration and voiding period.
Results suggest the importance of the NLRP3 inflammasome in the induction of inflammation and bladder dysfunction secondary to bladder outlet obstruction. Arresting these processes with NLRP3 inhibitors may prove useful to treat the symptoms that they produce.
虽然膀胱出口梗阻会引发膀胱的炎症反应,进而导致膀胱过度活动症和纤维化,但对于引发这一过程的机制却知之甚少。NLRs(核苷酸结合寡聚化结构域样受体)及其形成的结构(炎性小体)已被确定为细胞损伤的传感器,包括压力诱导的损伤,也是炎症的触发因素。最近我们在尿路上皮中发现了这些结构。在本研究中,我们评估了NLRP3(含NACHT、LRR和PYD结构域蛋白3)炎性小体在膀胱出口梗阻导致的膀胱功能障碍中的作用。
通过插入外径为1mm的经尿道导管、在尿道周围系上丝线结扎并移除导管,在雌性大鼠中制造膀胱出口梗阻。未治疗和假手术的大鼠作为对照。对患有膀胱出口梗阻的大鼠每天口服赋形剂(10%乙醇)或10mg/kg格列本脲(一种NLRP3抑制剂),持续12天。评估炎性小体活性、膀胱肥大、炎症和膀胱功能(尿动力学)。
膀胱出口梗阻增加了尿路上皮炎性小体活性、膀胱肥大和炎症,并减少了排尿量。格列本脲阻断了炎性小体的激活,减轻了肥大并预防了炎症。从机制上来说,格列本脲还通过增加逼尿肌收缩持续时间和排尿期,减轻了排尿量的减少。
结果表明NLRP3炎性小体在膀胱出口梗阻继发的炎症和膀胱功能障碍的诱导中具有重要作用。用NLRP3抑制剂阻止这些过程可能对治疗它们所产生的症状有用。